Incidence rates and predictors of microvascular and macrovascular complications in patients with type 2 diabetes: Results from the longitudinal global discover study.

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

Micro- and macrovascular complications are a major cause of morbidity and mortality in people with type 2 diabetes (T2D). We sought to understand the global incidence rates and predictors of these complications.

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): Am Heart J

Title: American heart journal

Publisher: Elsevier BV

ISSN (Electronic): 1097-6744

ISSN (Print): 0002-8703

Publication date (Electronic): Jan 2022

Volume: 243

Affiliations

[1 ] Division of Cardiology, Saint Luke's Mid America Heart Institute, Kansas City, Missouri; Department of Medicine, University of Missouri, Kansas City, Missouri.

[2 ] Diabetes Research Centre, University of Leicester, Leicester.

[3 ] Division of Cardiology, Saint Luke's Mid America Heart Institute, Kansas City, Missouri.

[4 ] AstraZeneca, Gaithersburg, Maryland.

[5 ] Evidera, Barcelona, Spain.

[6 ] AstraZeneca, Cambridge.

[7 ] Departamento de Medicina Interna, Rio de Janeiro State University, Rio de Janeiro, Brazil.

[8 ] Institute of Environmental Medicine, AstraZeneca Gothenburg, Mölndal, Sweden and Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden.

[9 ] Department of Endocrinology and Metabolism, Peking University People's Hospital, Beijing, China.

[10 ] AstraZeneca, Madrid, Spain.

[11 ] Center for Outcomes Research and Clinical Epidemiology, Pescara, Italy.

[12 ] AstraZeneca, Luton.

[13 ] Leibniz Center for Diabetes Research at Heinrich Heine University, German Diabetes Center, Düsseldorf, Germany.

[14 ] Endocrinology Research Centre, Diabetes Institute, Moscow, Russian Federation.

[15 ] Graduate School of Medicine, Osaka University, Osaka, Japan.

[16 ] Department of Diabetes and Endocrinology, Royal Liverpool University Hospital, Liverpool.

[17 ] Graduate School of Medicine, Juntendo University, Tokyo, Japan.

[18 ] Division of Cardiology, Saint Luke's Mid America Heart Institute, Kansas City, Missouri; Department of Medicine, University of Missouri, Kansas City, Missouri; The George Institute for Global Health and University of New South Wales, Sydney, Australia.

Article

Publisher Item ID: S0002-8703(21)00433-6

DOI: 10.1016/j.ahj.2021.10.181

PubMed ID: 34666013

SO-VID: 4bd41c41-de87-4dec-936f-175e69fe6c16

History

Data availability:

Comments

Comment on this article

scite_

Cited by 11

See all cited by